Your analysis makes good sense with clear rationality. In particular, the impact of GLP-1s on Obstructive Sleep Apnea (OSA) and subsequently on ResMed’s volumes is a core uncertainty for the years ahead. However, I remain confident that there are much more penetrations of continuous positive airway pressure (CPAP) therapy to people in developed and developing countries in particular.
Having noted the impact of GLP-1s on RMD share price, the price goes up and up as we are worrying and writing.
Looking at RSI (14 & 30 days line) technical indications, it is not in overbought territory yet.
Your analysis makes good sense with clear rationality. In...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$32.96 |
Change
0.210(0.64%) |
Mkt cap ! $20.46B | |||
| Open | High | Low | Value | Volume |
| $32.86 | $33.12 | $32.85 | $92.47M | 2.801M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 717 | $32.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $32.98 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$33.00 |
Change
0.210 ( 0.59 %) |
||||
| Open | High | Low | Volume | ||
| $32.89 | $33.11 | $32.86 | 421229 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| RMD (ASX) Chart |